📈 Sun Pharma's $12B Bid for Organon Signals Largest Indian Pharma M&A
📺 Broadcast Briefings
⚡📺 Television Broadcast
⚡️ Quick Scoop
⚠️ This data is AI-generated and must be verified by the reader. Verify from source.
💼 Bid Details: Sun Pharma plans a binding offer of $12 billion for Organon, after completing a 3-month due diligence and finalizing financing with three global banks.
🤝 Competitive Landscape: Other bidders include a buyout fund and a strategic investor consortium, including a European Union buyout fund.
🏥 Organon's Background: Organon specializes in women's health with a market capitalization of approximately $1.5 billion; it is a spin-off from MSD in 2021 and carries debt exceeding $8 billion.
📊 Financial Implications: Sun Pharma holds $3.2 billion net cash; combined net debt to EBITDA projected to fall to about 2x from current 4x, highlighting a significant but manageable leverage increase.
📉 Market Reaction: The stock dropped around 3% due to concerns over increased leverage from the acquisition.
🏆 Deal Significance: This acquisition would be the largest global M&A involving an Indian pharma firm, reflecting Sun Pharma's most ambitious overseas expansion effort.
